pharmacistlinx Medical News about Streptococcus pneumoniae

Email
Password
Remember me
Forgot your Password?
Invite Code?

Home
General Pharmacy

Messages

Conferences

Jobs

Newsletters

My Library

Topics in
Pharmacy

Adverse Drug Reactions

Antimicrobials

Basic Science

Cardiac/Hypertension

Chemotherapy/Oncology

Complementary Medicine

Dosing

Drug Approvals

Drug Interactions

Drug Resistance

Drug Trials

Drug/Product Alerts

Economics of Medicine

Major Studies

Neuro/Psych pharmacology

Other Drugs

Over The Counter (OTC)

Pain Medicine

Patient Counseling

Pharmacoeconomics

Pharmacokinetics

Pharmacy Management

Popular Press

Stomach/GI

Help

Resource Center

RSS News Feeds

Send Newsletter
to a Friend

Sponsor

Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website

Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae
Clinical Therapeutics, 01/22/08

Email This Article

Save in My Library

Free Abstract

Noreddin AM et al. - Based on these simulations, garenoxacin 400 mg QD, gemifloxacin 320 mg QD, and moxifloxacin 400 mg QD appeared likely to achieve target serum and ELF concentrations against S pneumoniae in hospitalized patients with CAP, with a low potential to select for resistance

Read a Different Specialty

Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT

Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology

Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

Dentist
Hospital Administrator
Nurse

Medical Students
Nurse Practitioner
Pharma/Drug Marketer

Pharmacist
Physician
Physician Assistants

Article Search

Keyword:

Search:

Published within:

Sort By:
Date Relevance